The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | ZUMA-24 preliminary analysis of axi-cel in the outpatient setting in patients with R/R LBCL
Olalekan Oluwole, MBBS, MD, Vanderbilt University Medical Center, Nashville, TN, discusses the ZUMA-24 study (NCT05459571), which evaluates the feasibility of administering axicabtagene ciloleucel (axi-cel) in an outpatient setting for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The study found that toxicity and response rates were comparable to the ZUMA-1 (NCT02348216) inpatient study, indicating that axi-cel can be safely administered to this patient population in an outpatient setting. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
